[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-nodules\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-nodules":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,52,87,114,136,165,189,226,256,280,304,330,355,383,407,433],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644877","intraoperative-longitude-latitude-depth-localization-versus-preoperative-ct-guided-percutaneous-lung-puncture-localization-for-08-2-cm-peripheral-pulmonary-nodules-100644877",false,"NCT07675889","Intraoperative Longitude-Latitude-Depth Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for 0.8-2 cm Peripheral Pulmonary Nodules","Intraoperative Longitude-Latitude-Depth Three-Dimensional Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for the Treatment of 0.8-2 cm Peripheral Pulmonary Nodules: A Multicenter, Randomized, Open-Label, Non-Inferiority Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed pulmonary nodule by non-contrast chest CT.\n* Age 18 to 80 years.\n* Expected survival time of at least 12 months.\n* Single peripheral pulmonary nodule with a diameter between 0.8 cm and 2 cm.\n* Chest CT characteristics meeting both of the following criteria:\n\n  1. Solid component proportion ≤50%.\n  2. Located subpleurally or in the outer one-third of the lung parenchyma.\n* Willing to undergo VATS-assisted sublobar resection.\n* No contraindications to pulmonary localization procedures or surgery.\n* Able to understand the study and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* Use of other localization methods or other surgical procedures.\n* Concurrent participation in another clinical study.\n* Pregnancy.\n* Unwillingness or inability to cooperate with participation in this study for any reason.","ALL","18 Years","80 Years",{"count":20,"type":21},274,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether intraoperative longitude-latitude-depth three-dimensional localization (LLD localization) is non-inferior to preoperative CT-guided percutaneous lung puncture localization for identifying 0.8-2 cm peripheral pulmonary nodules in adults undergoing video-assisted thoracoscopic surgery (VATS)-assisted sublobar resection. It will also evaluate the safety and perioperative effectiveness of the two localization methods. The main questions it aims to answer are:\n\n1. Is the localization accuracy rate of LLD localization non-inferior to that of CT-guided percutaneous lung puncture localization?\n2. Does LLD localization improve perioperative outcomes, including localization time, postoperative recovery, pain, quality of life, and perioperative complication rates?\n\nResearchers will compare LLD localization with CT-guided percutaneous lung puncture localization to determine whether LLD localization provides comparable localization accuracy while reducing procedure-related complications and improving perioperative outcomes.\n\nParticipants will:\n\n1. Be randomly assigned in a 1:1 ratio to either the LLD localization group or the CT-guided percutaneous lung puncture localization group.\n2. Undergo pulmonary nodule localization using the assigned localization method.\n3. Receive VATS-assisted sublobar resection following localization.\n4. Be assessed for localization accuracy, perioperative complications, localization time, postoperative chest drainage tube removal time, oxygenation index, postoperative hospital stay, pain scores, and quality-of-life outcomes.\n5. Complete follow-up assessments at 1, 3, and 6 months after surgery.",[27,28,29],"Pulmonary Nodule, Solitary","Peripheral Pulmonary Nodules","Pulmonary Nodules",[31,32,33,34,35,36,37,38],"Peripheral Pulmonary Nodule","Pulmonary Nodule Localization","Longitude-Latitude-Depth Localization","CT-Guided Percutaneous Localization","Video-Assisted Thoracoscopic Surgery","Sublobar Resection","Randomized Controlled Trial","Non-Inferiority Trial","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":21},"2026-07-01",{"date":47,"type":21},"2028-07-01",{"name":49,"class":50},"Qilu Hospital of Shandong University","OTHER",4,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100641818","deep-learning-time-series-prediction-of-long-term-growth-patterns-of-pulmonary-ground-glass-nodules-using-serial-ct-100641818","NCT07647692","Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT","Development and Multi-Cohort Validation of a Deep Learning Spatiotemporal Model for Predicting Long-Term Progression of Pulmonary Ground-Glass Nodules Using Serial Thoracic CT","GGN-Trajectory","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Persistent pulmonary ground-glass nodule (pGGN or mGGN, 5-30 mm) on thin-slice chest CT (slice thickness ≤ 1.5 mm).\n* Baseline and follow-up thin-slice chest CTs of sufficient quality for 3D segmentation and registration.\n* Minimum interval between any two consecutive CTs \\> 1 month.\n* Complete baseline clinical data available (age, sex, smoking history, family history of malignancy, relevant comorbidities).\n\nCohort-specific inclusion\n\n* Group 1 (Development): surgical resection of the target GGN at PKUPH between Jan 2007 - Jun 2025, with ≥ 2 pre-operative thin-slice CTs available.\n* Group 2 (Surgical internal test): surgical resection at PKUPH between Jul 2025 - Jan 2026, with ≥ 2 pre-operative thin-slice CTs available.\n* Group 3 (Non-surgical internal test): non-operative management at PKUPH between Jan 2020 - Dec 2025, with ≥ 3 thin-slice CTs of the target GGN available.\n* Group 4 (Prospective external validation): prospective enrollment after model lock at participating centers, baseline CT plus ≥ 2 planned routine follow-up thin-slice CTs.\n\nExclusion Criteria:\n\n* Coexisting severe pulmonary disease that obscures evaluation of the target GGN (e.g., active pulmonary tuberculosis, severe interstitial lung disease).\n* Prior history of any other thoracic malignancy, or active extrathoracic malignancy under treatment within 5 years, that would confound interpretation of the target GGN.\n* CT image quality insufficient for registration and feature extraction (severe motion artifact, slice thickness \\> 1.5 mm at any required timepoint, or extensive metallic artifact projecting over the target GGN).\n* Pure solid nodule with no ground-glass component.\n* Target GGN already received treatment (resection, ablation, or radiotherapy) prior to the baseline CT used in this study.",{"count":61,"type":21},4750,"5 Years","OBSERVATIONAL","Pulmonary ground-glass nodules (GGNs) are commonly found on chest CT scans. Some stay stable for years, while others slowly or rapidly turn into lung cancer. Doctors currently follow these nodules with repeated CT scans, but it is difficult to tell ahead of time which nodules will progress, how fast they will progress, and which ones can be safely monitored rather than immediately treated.\n\nThis observational study aims to develop and validate an artificial intelligence (AI) model that uses each patient's series of CT scans over time to predict the long-term growth behavior of a GGN. The research team will collect three retrospective single-center cohorts from Peking University People's Hospital (a development cohort and two internal test cohorts, one from surgically resected patients and one from non-operated patients followed by serial CT) as well as a prospective multi-center validation cohort enrolled after the AI model is locked.\n\nFor every patient, each GGN is automatically segmented in three dimensions on every CT scan. A deep learning model extracts imaging features at each timepoint and feeds the sequence of features, together with the actual times between scans, into a time-aware sequence model. The model is trained to predict (i) whether the nodule will show radiological progression at 1, 3, and 5 years after baseline, and (ii) which of four long-term growth patterns the nodule will follow: stable, slow progression, slow-then-rapid progression, or rapid progression. In patients who were ultimately resected, the histopathological diagnosis serves as a secondary reference standard.\n\nThis is an observational study. No experimental treatment is given. All CT scans and clinical visits are part of routine clinical care.",[29,66,67],"Lung Neoplasms","Adenocarcinoma of Lung",[69,70,71,72,73,74,75,76],"Ground Glass Opacity","Ground-Glass Nodule","Longitudinal CT","Time-Series Analysis","Growth Trajectory","Volume Doubling Time","Deep Learning","Radiomics","2026-06-10",{"date":79,"type":43},"2026-06-15",{"date":81,"type":21},"2026-06-01",{"date":83,"type":21},"2031-06-01",{"name":85,"class":50},"Peking University People's Hospital",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":86},"100637941","application-of-electromagnetic-navigation-system-in-pulmonary-nodule-localization-100637941","NCT07595120","Application of Electromagnetic Navigation System in Pulmonary Nodule Localization","Electromagnetic Navigation-Guided Versus CT-Guided Localization of Pulmonary Nodules: A Multicenter, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. Solitary single nodule, scheduled for lung nodule puncture and localization;\n3. Chest CT (lung window mode) showing a maximum nodule diameter ≤ 2 cm;\n4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2;\n5. Voluntary participation, with signed informed consent.\n\nExclusion Criteria:\n\n1. Not suitable for video-assisted thoracoscopic surgery;\n2. The distance between the center of the lesion and the dome of the diaphragm is \\\u003C 3 cm;\n3. History of thoracic adhesion due to previous thoracotomy or pleural infection;\n4. Patients judged by the investigator to be unsuitable for preoperative transthoracic or transbronchial localization;\n5. Inability to complete follow-up or poor compliance.",{"count":95,"type":21},400,[24],"This study aims to design and conduct a multicenter, prospective, randomized controlled post-market clinical trial to validate the clinical efficacy of high-precision electromagnetic navigation technology.",[29,99],"Early-Stage Lung Cancer",[101,102,103,104],"ENB","CT-guided Percutaneous","pulmonary nodules","localization","2026-05-16",{"date":107,"type":43},"2026-05-19",{"date":109,"type":21},"2026-05",{"date":111,"type":21},"2027-04",{"name":113,"class":50},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":86},"100634851","robotic-assisted-bronchoscopy-guided-synchronous-biopsy-and-radiofrequency-ablation-for-pulmonary-nodules-100634851","NCT07545057","Robotic-Assisted Bronchoscopy-Guided Synchronous Biopsy and Radiofrequency Ablation for Pulmonary Nodules","A Feasibility Study on Synchronous Biopsy and Radiofrequency Ablation for Pulmonary Nodules Under Robotic-Assisted Bronchoscopy: A Prospective, Single-Arm, Open-Label Clinical Study：ROBUST Study","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Chest CT indicates pulmonary nodules, highly suspected of being malignant;\n* Size of pulmonary nodules: 8 mm \\\u003C maximum diameter ≤ 30 mm, and the number of pulmonary nodules requiring intervention ≤ 3;\n* Preoperative imaging evaluation indicates no clear lymph node metastasis or distant metastasis (cT1N0M0);\n* Multidisciplinary evaluation shows that the patient cannot tolerate surgery and radiotherapy, or the patient refuses surgery and radiotherapy after full informed consent;\n* The patient understands and agrees to receive synchronous biopsy and ablation treatment under robotic-assisted bronchoscopy and signs a written informed consent form.\n\nExclusion Criteria:\n\n* Patients who cannot tolerate general anesthesia due to advanced age or severe cardiopulmonary diseases, or other reasons;\n* The target nodule has been diagnosed as a malignant tumor or metastasis;\n* Patients with severe bleeding tendency or uncorrectable coagulation disorder (platelet count \\\u003C 50×10\\^9 \u002FL, prothrombin time \\> 18s, prothrombin activity \\\u003C 40%);\n* Severe pulmonary fibrosis and pulmonary hypertension;\n* Anticoagulant or anti-platelet drugs have not been discontinued for the required time before surgery;\n* Implanted cardiac pacemaker, defibrillator, or other electronic implants;\n* Presence of important blood vessels that cannot be avoided along the biopsy path;\n* Other conditions that the investigators consider not suitable for the patient to participate in this study.","100 Years",{"count":123,"type":21},76,[24],"This is a prospective, single-arm, open-label clinical study. The primary study objective is to evaluate the feasibility of synchronous biopsy and radiofrequency ablation for pulmonary nodules under robotic-assisted bronchoscopy.",[29],"2026-04-22",{"date":129,"type":43},"2026-04-28",{"date":131,"type":21},"2026-05-01",{"date":133,"type":21},"2027-12-31",{"name":135,"class":50},"Shanghai Chest Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":86},"100632723","study-of-collection-and-analysis-of-clinical-anamnestic-functional-biological-data-through-the-support-of-artificial-intelligence-to-evaluate-the-possibility-of-defining-a-digital-twin-of-the-lung-luce-100632723","NCT07517393","Study of Collection and Analysis of Clinical, Anamnestic, Functional, Biological Data Through the Support of Artificial Intelligence to Evaluate the Possibility of Defining a Digital Twin of the Lung (LUCE)","LUCE: LUng Cancer (r)Evolution","Inclusion Criteria:\n\n* Men or women aged ≥ 18 years who will perform a smdc photon count chest CT scan\n* written informed consent.\n\nExclusion Criteria:\n\n* Lack of information regarding anamnestic data\n* any reason why the investigator deems the patient unenrollable in the practice.",{"count":144,"type":21},1000,"This research study aims to retrospectively and prospectively analyze the clinical, anamnestic, functional, biological data of patients who have performed or will perform non-contrast chest photon count CT.\n\nThe use of contrast medium is evaluated by the physician. Main objective The study aims to understand how many people who undergo non-contrast photon-counting chest CT have: lung nodules, chest tumors, and other non-cancerous lung diseases.\n\nSecondary objectives\n\n* Analyze the data with the help of artificial intelligence to create a \"digital twin\" of the lung, that is, a virtual copy of the lung that allows you to study and simulate the behavior of the lung for research and analysis purposes, without directly intervening on the patient.\n* Follow any suspicious lung changes over time to understand how they change and whether they are linked to clinical, biological, or laboratory parameters.\n\nThe enrollment phase will last 12 months and will begin with the approval of the study. At this stage, clinical data already present in the patient's medical record and data relating to the photon count CT examination will be collected. After the enrollment phase, the patient will be observed for a further total duration of 10 years: in particular, a follow-up visit will be arranged at two, five and ten years. More specifically, if there are no radiological elements that require scheduling a visit to the center, the patient will be contacted by telephone for a telematic update of the data. If, however, pulmonary alterations are identified during the study, the patient will be referred to the Reference Operating Unit, as per clinical practice, to continue with the most appropriate personalized diagnostic-therapeutic process. In these cases, the patient will be contacted by telephone and an appointment with the institution will be suggested.",[147,29,148],"Thoracic Neoplasm","Non-oncological Pulmonary Pathologies",[150,151,152,153,154],"Lung","Artificial Intelligence","observational","Photon Counting Computed Tomography","thoracic malignancies","RECRUITING","2026-04-01",{"date":158,"type":43},"2026-04-08",{"date":160,"type":21},"2026-04",{"date":162,"type":21},"2036-03",{"name":164,"class":50},"Casa di Cura Dott. Pederzoli",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":86},"100630454","cadherin-3cdh3-targeted-pet-in-lung-malignant-tumors-100630454","NCT07487883","Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors","A Single-arm, Open-label, Single-center Clinical Study to Evaluate CDH3-targeted Positron Emission Tomography (PET) for Lung Malignant Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1;\n2. Availability of complete clinical and imaging data;\n3. Life expectancy ≥ 12 weeks;\n4. Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹\u002FL or neutrophils ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, Hb ≥ 90 g\u002FL; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT\u002FAST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN;\n5. Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria;\n6. Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks;\n7. Ability to provide adequate tumor tissue for testing and research.\n\nExclusion Criteria:\n\n1. Women who are planning pregnancy, pregnant, or breastfeeding;\n2. History of other malignant tumors or prior receipt of other anti-tumor therapies;\n3. Poor or missing PET scan image quality of the probe that fails to meet analysis standards;\n4. Presence of claustrophobia or other mental illnesses;\n5. Any other conditions deemed by the investigators as inappropriate for participation in this study.",{"count":173,"type":21},80,"Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.",[176,177,29,178],"Non-Small Cell Lung Cancer","Malignant Neoplasm","PET\u002FCT",[177,178,176,180],"Pulmonary nodules","2026-03-27",{"date":183,"type":43},"2026-04-02",{"date":185,"type":43},"2026-03-18",{"date":187,"type":21},"2027-07-30",{"name":85,"class":50},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":200,"studyType":63,"phases":4,"briefSummary":201,"conditions":202,"keywords":207,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":86},"100597373","shape-sensing-robotic-assisted-bronchoscopy-for-diagnosis-of-peripheral-pulmonary-nodules-in-korea-100597373","NCT07057648","Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea","Shape-sensing Robotic-assisted Bronchoscopy (ssRAB) for Diagnosis of Peripheral Pulmonary Nodules: A Prospective Cohort Study in Korea (the ULSAN-ION Study)","ULSAN-ION","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Solid or part-solid peripheral pulmonary nodules confirmed on chest computed tomography (CT)\n* Patients requiring histological diagnosis as determined by the treating physician\n* Patients eligible for bronchoscopy procedure\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or equivalent functional status allowing procedure under sedation or general anesthesia\n\nExclusion Criteria:\n\n* Pure ground glass opacity nodules\n* Bleeding tendency defined as platelet count less than 50,000\u002FμL or International Normalized Ratio (INR) greater than 1.5\n* Severe cardiopulmonary dysfunction precluding deep sedation or general anesthesia\n* Pregnant or breastfeeding women\n* Life expectancy less than 6 months as assessed by the treating physician\n* Inability or unwillingness to provide informed consent\n* Absolute contraindication to bronchoscopy including:\n\n  * Severe hypoxemia (oxygen saturation \\\u003C90% on room air)\n  * Severe pulmonary hypertension\n  * Recent myocardial infarction (within 6 weeks)\n  * Unstable angina\n  * Malignant arrhythmias\n* Participation in another interventional clinical trial that may interfere with study procedures or outcomes","19 Years",{"count":199,"type":21},100,"6 Months","What is this study about? This study tests a new robotic technology to take tissue samples from lung nodules (small spots in the lungs). Some lung nodules are cancer, but doctors need a tissue sample to know for sure.\n\nWhat is the problem? Current methods to get tissue from lung nodules only work about 7 out of 10 times. When they don't work, doctors may need riskier procedures.\n\nWhat is the new technology? The new technology is called robotic bronchoscopy (ssRAB). It uses a robot with special sensors to guide a thin tube more accurately to lung nodules than current methods.\n\nWho can join? Adults aged 19 or older who have lung nodules that need tissue sampling and are healthy enough for the procedure.\n\nWhat happens? Participants will have the robotic procedure while asleep under anesthesia. The robot guides a thin tube to the lung nodule to take a small tissue sample. Participants are watched for problems and followed for 6 months.\n\nWhat are the risks and benefits? The new technology may be more accurate and safer than current methods. The main risks are small chance of lung collapse or bleeding, similar to regular procedures.\n\nWhy is this important? This study will show if the new robotic technology works well and is safe in Korea. If successful, it could help diagnose lung cancer earlier and more accurately.\n\nThis study will include 100 people at Ulsan University Hospital in Korea.",[203,204,29,205,206],"Lung Nodules","Peripheral Lung Lesions","Lung Cancers","Bronchoscopy",[208,209,210,211,212,203,213,214,215,216],"Shape-sensing robotic-assisted bronchoscopy","ssRAB","Robotic bronchoscopy","Peripheral lung nodules","Diagnostic yield","Navigation bronchoscopy","Lung biopsy","Korea","Prospective cohort","2026-02-10",{"date":219,"type":43},"2026-02-13",{"date":221,"type":43},"2025-07-09",{"date":223,"type":21},"2027-05-31",{"name":225,"class":50},"Ulsan University Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":86},"100624399","tubeless-strategy-for-enhanced-recovery-after-sublobar-resection-100624399","NCT07409129","Tubeless Strategy for Enhanced Recovery After Sublobar Resection","Tubeless Strategy Within an Enhanced Recovery After Surgery (ERAS) Protocol for Thoracoscopic Sublobar Resection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Scheduled for uniportal or multiportal video-assisted thoracoscopic surgery (VATS) for sublobar resection (wedge or segmentectomy).\n* Presence of peripheral lung nodules ≤ 2 cm in diameter and ≤ 2 cm from the pleura, confirmed by CT scan.\n* Ability to understand and provide written informed consent.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n\nExclusion Criteria:\n\n* Severe pleural adhesions or fibrosis that would preclude non-intubated anesthesia or tubeless approach.\n* Severe cardiopulmonary dysfunction: FEV1 \\\u003C 50% predicted, DLCO \\\u003C 60% predicted, heart failure (NYHA class III-IV), or unstable angina.\n* Pregnancy or lactation (confirmed by urine test if applicable).\n* Inability to tolerate one-lung ventilation due to anatomical or physiological reasons.\n* History of ipsilateral thoracic surgery.\n* Active pulmonary infection, uncontrolled diabetes, or other comorbidities that increase surgical risk.\n* Participation in another interventional trial within 30 days.","75 Years",{"count":235,"type":21},138,[24],"This is a prospective, randomized controlled clinical trial conducted at a single center. The study aims to evaluate whether a \"tubeless\" strategy can enhance recovery for patients undergoing minimally invasive thoracoscopic sublobar resection (wedge or segment resection) for small lung nodules.\n\nParticipants will be randomly assigned to one of two groups:\n\n* The experimental group will receive the \"tubeless\" strategy, which includes non-endotracheal intubation anesthesia (using a laryngeal mask) and no routine chest tube drainage after surgery.\n* The control group will receive the traditional strategy, which includes double-lumen endotracheal intubation anesthesia and routine chest tube drainage.\n\nThe main goal is to compare the rate of achieving high-quality fast-track recovery at 24 hours after surgery between the two groups. This study will provide evidence on whether the tubeless approach can help patients recover faster and more comfortably without compromising safety.",[29,239,240,36],"Early Stage Lung Cancer (I and II)","Thoracoscopic Surgery",[242,243,244,245,246,247],"Tubeless Surgery","Non-intubated Anesthesia","Enhanced Recovery After Surgery","Sublobar resection","Wedge Resection","Segmentectomy","2026-02-06",{"date":219,"type":43},{"date":251,"type":21},"2026-02-01",{"date":253,"type":21},"2026-09-01",{"name":255,"class":50},"The First Affiliated Hospital of Guangzhou Medical University",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":86},"100623341","non-intubated-versus-intubated-anesthesia-for-thoracoscopic-sublobar-resection-100623341","NCT07395375","Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection","A Multicenter, Randomized, Controlled Trial of Non-Intubated Spontaneous Breathing Anesthesia Versus Intubated Mechanical Ventilation Anesthesia in Thoracoscopic Sublobar Resection: A Stratified Analysis Study Focusing on Safety and Recovery Quality","NIVA-TSLR","Inclusion Criteria:\n\n1. Aged 18 to 80 years (inclusive).\n2. Scheduled for elective, uniportal or single utility port video-assisted thoracoscopic sublobar resection (wedge resection or simple anatomical segmentectomy).\n3. Preoperative CT diagnosis of a peripheral pulmonary nodule meeting: maximum diameter ≤ 2.0 cm and outer edge ≤ 2.0 cm from the visceral pleura.\n4. American Society of Anesthesiologists (ASA) physical status I or II.\n5. Preoperative pulmonary function: FEV1% ≥ 60% of predicted.\n6. Preoperative arterial blood gas analysis (room air): PaO₂ ≥ 80 mmHg and PaCO₂ ≤ 45 mmHg.\n7. Body Mass Index (BMI) between 18.0 and 28.0 kg\u002Fm².\n8. Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Cardiovascular: NYHA class ≥ III, unstable angina, acute myocardial infarction within 3 months, or severe arrhythmia requiring medication.\n2. Respiratory: Severe COPD (GOLD 3 or 4), symptomatic interstitial lung disease, resting SpO₂ \\\u003C 92% on room air, or severe pulmonary hypertension (estimated systolic PAP \\> 50 mmHg).\n3. Airway Risk: Modified Mallampati score ≥ 3, mouth opening \\\u003C 3 cm, or other predictors of difficult airway management.\n4. Radiological: Preoperative CT suggesting extensive pleural adhesion, moderate or large pleural effusion, or mediastinal lymph nodes \\> 1.5 cm short axis.\n5. Contraindications to Regional Anesthesia: Infection\u002Ftumor at the block site, patient refusal, or allergy to local anesthetics.\n6. Coagulopathy: Platelet count \\\u003C 100×10⁹\u002FL, INR \\> 1.5, or use of anticoagulants that cannot be safely discontinued perioperatively.\n7. Other: Severe hepatic or renal dysfunction, previous ipsilateral thoracic surgery, pregnancy or lactation, active psychiatric or cognitive disorders, or participation in another conflicting clinical trial.",{"count":265,"type":21},1600,[24],"This is a large clinical study that compares two different types of anesthesia for patients undergoing a specific kind of minimally invasive lung surgery (thoracoscopic sublobar resection) to remove small, early-stage lung nodules.\n\nThe study aims to find out if a newer anesthesia method, known as \"non-intubated anesthesia\" (where patients breathe on their own with the help of a laryngeal mask airway and nerve blocks for pain control), is as safe as the traditional \"intubated anesthesia\" (which uses a breathing tube and a machine to breathe for the patient).\n\nThe main goals of the study are, in order:\n\n1. Safety First: To confirm that the non-intubated method does not lead to more lung complications within 30 days after surgery compared to the traditional method.\n2. Effectiveness: If it is proven safe, the study will then check if patients receiving the non-intubated anesthesia have a better quality of recovery in the first 24 hours after surgery (e.g., less pain, fewer side effects like a sore throat, and a faster return to normal activities).\n\nApproximately 1600 patients from multiple hospitals will be randomly assigned (like flipping a coin) to receive one of the two anesthesia methods. Neither the patients nor the surgeons will be told which group the patient is in when assessing the main outcomes after surgery, to ensure the results are fair and unbiased.\n\nThe results of this study will provide high-quality evidence to help doctors and patients choose the best and most comfortable anesthesia option for this type of lung surgery.",[29,66,269],"Thoracic Surgery",[271,272,35,244,37],"Non-intubated Thoracic Surgery","Lung Sublobar Resection",{"date":274,"type":43},"2026-02-09",{"date":276,"type":21},"2026-03-01",{"date":278,"type":21},"2027-08-01",{"name":255,"class":50},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100622920","percutaneous-robotic-navigation-microwave-ablation-versus-ct-guided-microwave-ablation-in-the-treatment-of-pulmonary-nodules-with-ground-glass-opacity-100622920","NCT07389889","Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity","Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 85 years\n2. Nodules measuring 3-30mm with ground-glass opacities constituting ≥75% of the lesion\n3. Preoperative clinical evaluation confirming no hilar or mediastinal lymph node metastasis and no distant metastasis\n4. Patients diagnosed as stage IA primary peripheral lung cancer according to the UICC 8th TNM staging system, and with one of the following conditions:\n\n   (i) cannot undergo surgical resection due to poor cardiopulmonary function or advanced age (ii) refusing or unwilling to undergo surgical resection (iii) with newly developed or residual pulmonary nodules after early-stage primary lung cancer surgery (iv) with unilateral lung disease who cannot undergo unilateral surgical resection (v)with multiple primary lung cancers unsuitable for surgical resection\n5. Preoperative ECOG physical status score is 0\u002F1\n6. ASA score is I-III\n7. Patients voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Smoking cessation duration \\\u003C2 weeks\n2. Lesions adjacent to pulmonary artery-vein main trunks\n3. Lesions near the hilum or adjacent to lobar bronchi\n4. Pregnancy or lactation status\n5. Severe mental disorders\n6. History of other malignancies within 5 years\n7. Unstable angina or myocardial infarction within 6 months with coronary angiography showing severe stenosis of major coronary branches\n8. Cerebral infarction or hemorrhage within 6 months\n9. Continuous systemic corticosteroid therapy within 1 month\n10. Patients or their authorized persons who do not wish to comply with the study protocol\n11. Patients with other investigator-assessed ineligibility for the trial","85 Years",{"count":289,"type":21},116,[24],"1. To compare the precision of robot-guided microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules.\n2. To evaluate the safety of robot-assisted microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules.\n3. Explore the application potential of robot navigation microwave ablation technology in the treatment of pulmonary nodules.",[29,293],"Ground-glass Opacity",[295],"ggo","2026-02-03",{"date":298,"type":43},"2026-02-05",{"date":251,"type":21},{"date":301,"type":21},"2029-02-01",{"name":303,"class":50},"Fujian Medical University Union Hospital",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":311,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":86},"100616177","effect-of-technology-assisted-preoperative-home-exercise-on-postoperative-handgrip-strength-muscle-endurance-and-psychological-distress-in-patients-with-pulmonary-nodules-undergoing-video-assisted-thoracoscopic-surgery-100616177","NCT07302217","Effect of Technology-Assisted Preoperative Home Exercise on Postoperative Handgrip Strength, Muscle Endurance, and Psychological Distress in Patients With Pulmonary Nodules Undergoing Video-Assisted Thoracoscopic Surgery","Effect of Technology-Assisted Intervention Program on Postoperative Handgrip Strength, Muscle Endurance, and Psychological Distress in Patients With Pulmonary Nodules","Inclusion Criteria:\n\n1. Patients with pulmonary nodules who are scheduled to undergo video-assisted thoracoscopic surgery for nodule resection (including wedge resection, segmentectomy, or lobectomy).\n2. Aged 20 years or older and assessed by a healthcare provider as medically suitable to participate in exercise training.\n3. At least one week between the date of enrollment and the scheduled surgery.\n4. Willing to provide written informed consent and complete all study procedures, including joining the LINE Official Account, participating in the exercise training, completing questionnaires, and undergoing outcome assessments.\n\nExclusion Criteria:\n\n1. Metastatic tumors or contraindications to exercise participation.\n2. Engagement in regular aerobic or resistance exercise within the past month (defined as ≥2 sessions per week, ≥30 minutes per session).\n3. Inability to communicate in Mandarin or Taiwanese.\n4. Inability to use technology-assisted applications (e.g., LINE APP).","20 Years",{"count":313,"type":21},60,[24],"This study aims to evaluate the effects of a technology-assisted preoperative home-based exercise program, delivered through a LINE Official Account and LINE BOT, on postoperative hand-grip strength, muscle endurance, and psychological distress in patients undergoing thoracoscopic pulmonary nodule resection. The study adopts a single-group pretest post-test design and plans to recruit 60 eligible patients.\n\nThe intervention consists of at least one week of home exercise training before surgery, incorporating aerobic, resistance, and breathing exercises. Education, guidance, and interactive feedback are provided through the LINE platform to support adherence and exercise performance. Outcomes will be assessed at three time points: baseline (T0), immediately before surgery (T1), and two weeks after surgery (T2).",[29],[318,319,320],"exercise","APP LINE","Lung nodule","2025-12-11",{"date":323,"type":43},"2025-12-24",{"date":325,"type":21},"2025-12-17",{"date":327,"type":21},"2026-12-31",{"name":329,"class":50},"National Taiwan University Hospital",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":346,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":86},"100614245","the-percutaneous-interventional-surgery-control-system-for-pulmonary-nodule-biopsy-100614245","NCT07277088","The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy","A Prospective, Single-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of the Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy","Inclusion Criteria:\n\n1\\) Age ranging from 18 years old to 80 years old, gender not restricted; 2) Patients with pulmonary nodules detected by chest CT, suspected to be malignant and judged by the researchers to require puncture biopsy for a clear diagnosis; 3) Pulmonary nodules with a long diameter greater than 8mm but not exceeding 30mm; 4) Have signed the informed consent form and voluntarily participate in this clinical study; 5) Can understand this research and cooperate with the research procedures, and can follow the requirements for follow-up observation.\n\nExclusion Criteria:\n\n1\\) Subjects with irreparable coagulation dysfunction, infectious lesions on the puncture path, lesions adjacent to organs or surrounded by large blood vessels, suspected pulmonary echinococcosis on imaging, patients on mechanical ventilation (with a ventilator), liver multilocular echinococcosis, coma or other patients who are uncooperative; 2) Those judged by the investigators to be unsuitable for chest percutaneous puncture surgery: such as severe pulmonary hypertension, pulmonary bullae, chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis; 3) Poor overall condition (multiple systemic metastases, severe infection, high fever), obvious cachexia, severe dysfunction of important organs, severe anemia and nutritional metabolic disorders that cannot be improved in the short term; 4) Those allergic to contrast agents or anesthetics; 5) Implantation of pacemakers; 6) Pregnant or lactating women, or those with a fertility plan during the clinical trial; 7) Patients who cannot cooperate with the doctor to complete the puncture surgery, such as known drug or alcohol addiction, mental and neurological diseases, intellectual disability, psychological disorders, etc.; 8) Those participating in another drug or medical device clinical trial (within 3 months of drug clinical trial or within 1 month of medical device clinical trial); 9) The target lesion has been diagnosed or has received treatment; 10) Other situations that the investigator deems not suitable for this clinical trial.",{"count":338,"type":21},158,[24],"This prospective, single-center, non-inferiority, randomized controlled clinical trial aims to evaluate the efficacy and safety of a percutaneous interventional surgical control system in performing percutaneous needle biopsy of pulmonary nodules, compared with conventional manual biopsy. The study will be conducted at Shanghai Chest Hospital and plans to enroll 158 patients who meet the indications for percutaneous transthoracic needle biopsy (PTNB) and have no contraindications. Participants will be randomly assigned to one of two groups: the experimental group will undergo PTNB assisted by the percutaneous interventional surgical control system, while the control group will receive traditional manual PTNB. The primary endpoint is diagnostic yield; secondary endpoints include technical success rate, number of needle adjustments, puncture time, total procedure time, radiation dose, and complication rates.",[29,342,343,344,345],"Lung Cancer (Diagnosis)","Percutaneous Needle Biopsy","Transthoracic Needle Biopsy","Robotic Assisted Intervention",[343,344,29,342,345],"2025-11-30",{"date":321,"type":43},{"date":350,"type":21},"2025-12-10",{"date":352,"type":21},"2027-05-30",{"name":354,"class":50},"Jiayuan Sun",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":382},"100604726","local-anaesthetic-spread-and-sensory-block-range-of-the-retro-superior-costotransverse-ligament-space-block-100604726","NCT07153263","Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block","Comparison of Local Anaesthetic Spread Between the Retro-superior Costotransverse Ligament Space Block and Thoracic Paravertebral Block: A Three-dimensional CT Reconstruction Imaging Study","Inclusion Criteria:\n\nPatients scheduled for CT-guided lung nodule localization under local anesthesia will be selected\n\n1. aged 18-80 years\n2. BMI 18-30 kg\u002Fm²\n3. ASA classification I-III\n\nExclusion Criteria:\n\n1. Allergy to the study drug or local anesthetic;\n2. History of opioid abuse;\n3. Pre-existing skin infection at the puncture site of ITPN or TPVB;\n4. Peripheral infectious neuropathy;\n5. Dysfunction of blood coagulation",{"count":363,"type":21},50,[24],"The aim of this clinical trial is to investigate the effects of local anesthetic diffusion range and sensory block range during retro-SCTLB(retro superior costotransverse ligament space block) and TPVB(thoracic paravertebral block) in patients undergoing CT-guided lung nodule localization. The main issue of the study is to determine the differences in the diffusion range and sensory block range of local anesthetics between the retro-SCTLB and TPVB nerve block methods.",[29,367],"Nerve Block",[369,370,371,372],"nerve block","TPVB","ITPB","rSCTL","2025-09-14",{"date":375,"type":43},"2025-09-16",{"date":377,"type":43},"2025-09-12",{"date":379,"type":21},"2026-09-30",{"name":381,"class":50},"Nanjing First Hospital, Nanjing Medical University",2,{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":86},"100520471","new-method-to-differentiate-benign-and-malignant-pulmonary-nodules-100520471","NCT06056999","New Method to Differentiate Benign and Malignant Pulmonary Nodules.","A New Method to Differentiate Benign and Malignant Pulmonary Nodules by Mass Spectrometry Combined With Artificial Intelligence.","Inclusion Criteria:\n\n* Age ≥18 years;\n* CT imaging shows the presence of pulmonary nodule \\\u003C3cm which is scheduled for puncture biopsy or surgery (i.e., the target lesion), the presence of ≥2 target lesions of the same type (categorized by density) are allowed;\n* Subjects are in good condition with Eastern Cooperative Oncology Group (ECOG) scale of 0-2;\n* Subjects with fair vital organ function, defined as: white blood cells ≥3.0×10\\^9\u002FL, platelets ≥75×10\\^9\u002FL, hemoglobin ≥90g\u002FL, alanine aminotransferase and aspartate aminotransferase ≤2.5 times the upper limit of normal values, and serum creatinine \\\u003C178μmol\u002FL;\n* Subjects must have the ability to understand and sign the informed consent in writing voluntarily.\n\nExclusion Criteria:\n\n* Imaging examination have suggested the possibility of metastasis at other sites;\n* ≥2 target lesions with different type categorized by density;\n* History of malignant disease;\n* Severe vascular lesions within the last 3 months, or known significant active infection, during acute\u002Fchronic tuberculosis infection, or severe cardiovascular and cerebrovascular diseases, dysfunction of liver and renal, or significant endocrine and metabolic disorders, or other serious concomitant diseases that are not controlled;\n* The specialist\u002Fsurgeon assessed that puncture or surgery is not available, with contraindication such as coagulation disorders, cardiorespiratory insufficiency, etc.;\n* History of uncontrolled epilepsy, central nervous system disease, or psychiatric disorders, that may affect the signing of informed consent;\n* Pregnant or breastfeeding women;\n* Other conditions deemed by the investigator to be unsuitable for enrollment.",{"count":391,"type":21},150,"The goal of this observational clinical trial is to establish a new method for differentiating benign and malignant pulmonary nodules by peripheral blood detection in patients with pulmonary nodules (\\\u003C3cm). The main questions it aims to answer is: How to combine blood metabolomic mass spectrometry detection and artificial intelligence image analysis to establish a new model for differentiating benign and malignant pulmonary nodules. Participants will be asked provide 4 mL peripheral blood for the test.",[29],[395,396,397],"differential diagnosis","benign and malignant pulmonary nodules","early diagnosis of lung cancer","2024-12-13",{"date":400,"type":43},"2024-12-18",{"date":402,"type":43},"2023-09-29",{"date":404,"type":21},"2025-07",{"name":406,"class":50},"China-Japan Friendship Hospital",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":4},"100568763","constructing-a-predictive-model-for-differentiating-between-benign-and-malignant-solid-pulmonary-nodules-based-on-clinical-and-imaging-features-100568763","NCT06685458","Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features.","Combined With Clinical and Imaging Features, the Prediction Model of Benign and Malignant Solid Pulmonary Nodules Was Constructed","Inclusion Criteria:\n\n* (1) All subjects provided CT imaging obtained from the Third Affiliated Hospital of Kunming Medical University within 2-week period prior to surgery; (2) Complete clinicopathological data of solid nodules were obtained; (3) Surgical intervention for one or more SPN; (4) No prior anti-tumor treatments like radiotherapy or chemotherapy; (5) Age 18 years or older.\n\nExclusion Criteria:\n\n* (1) Patients with incomplete imaging data or medical records; (2) Lung infections that could affect image analysis; (3) Significant respiratory movement artifacts in images impairing imaging analysis; (4) Inconsistent locations of SPN in postoperative pathology reports and preoperative CT images.",{"count":415,"type":21},320,"Study Objective:\n\nTo comprehensively analyze the preoperative clinical and imaging characteristics of solid pulmonary nodules, investigate the risk factors associated with malignant solid pulmonary nodules, and provide a reference for preoperative treatment decisions.\n\nSignificance of the Study:\n\nAccording to the 2020 Global Cancer Report, lung cancer remains the leading cause of cancer-related deaths worldwide. While the majority of patients with stage I lung cancer achieve long-term survival, survival rates for advanced-stage patients are extremely low. Early screening, diagnosis, and treatment of lung cancer are crucial.\n\nWith the widespread implementation of early lung cancer screening, a growing number of pulmonary nodules are being detected, among which solid pulmonary nodules constitute a significant proportion. Unlike ground-glass nodules, accurately distinguishing between benign and malignant solid nodules is critical for determining appropriate treatment strategies. For benign solid nodules, follow-up observation is the preferred approach, whereas early surgical intervention is essential for malignant solid nodules.\n\nAlthough previous studies have explored the correlation between clinical and imaging characteristics, they have not conducted systematic analyses, and most have been based on small sample sizes. Therefore, this study aims to conduct a comprehensive analysis of preoperative clinical and imaging characteristics, build a predictive model to differentiate between benign and malignant solid pulmonary nodules, and provide a reliable reference for selecting treatment strategies.",[418,419,29],"Lung Cancer","Solid Pulmonary Nodules",[421,422,423],"Lung Cancer Screening","Nodule Malignancy Prediction","Preoperative Imaging Analysis","2024-11-10",{"date":426,"type":43},"2024-11-12",{"date":428,"type":21},"2024-11-15",{"date":430,"type":21},"2025-02-20",{"name":432,"class":50},"The Third Affiliated Hospital of Kunming Medical College.",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":441,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":22,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":450,"leadSponsor":452,"locationsCount":86},"100568110","the-sequence-trial-evaluating-diagnostic-yield-of-robotic-assisted-bronchoscopy-when-staging-ebus-is-performed-first-or-second-in-the-same-procedure-100568110","NCT06676956","The SEQUENCE Trial: Evaluating Diagnostic Yield of Robotic-assisted Bronchoscopy When Staging EBUS is Performed First or Second in the Same Procedure","The SEQUENCE Trial: Should Endobronchial Ultrasound QUeue bEfore or eNsuing to robotiC-assisted Bronchoscopy for pEripheral Pulmonary Nodule Biopsy? A Patient Randomized Control Trial Assessing the Effect of the Ordering of Robotic-assisted Bronchoscopy and Linear EBUS During the Same Anesthesia Event on Diagnostic Yield From Peripheral Pulmonary Nodule Biopsy","SEQUENCE","Inclusion Criteria:\n\n* Peripheral Pulmonary Nodule undergoing a robotic-assisted bronchoscopy\n\nExclusion Criteria:\n\n* lymph nodes that are enlarged or PET avid on CT prior to procedure",true,{"count":415,"type":21},[24],"Robotic-assisted bronchoscopy (RaB) has afforded proceduralists the ability to accurately reach the periphery of the lung for biopsy of pulmonary nodules1. This has paved the way for patients to undergo both biopsy of a peripheral nodule and a staging linear endobronchial ultrasound (EBUS) in the same anesthesia event, promoting quicker throughput from discovery of a lesion to guideline-adherent treatment2. Further, introduction and mainstream utilization of cone-beam CT (CBCT) has provided the bronchoscopist the ability to refine needle position with tool-in-lesion confirmation3. While there are no randomized clinical trials promoting efficacy of RaB and CBCT in comparison with other bronchoscopic methods, in single center retrospective studies, diagnostic yield has consistently proven to be in the 70-85% range, superior to prior technologies4-6.\n\nOne of the limitations of utilization of RaB and CBCT is the detrimental effect that atelectasis plays in the bronchoscopy procedure. This can lead to false positive radial EBUS (rEBUS) signals and non-diagnostic procedures7. This incidence of atelectasis has been evaluated prospectively, using a protocol featuring 8-10 cmH2O of PEEP and limiting hyperoxia8, and results suggest this ventilator strategy does an adequate job preventing intraprocedural lung collapse. However, this study only evaluated incidence of atelectasis and did not elaborate on its impact on diagnostic yield.\n\nFurther unknown is the optimal sequence of performance of RaB and a staging linear EBUS in patients with a radiographically normal mediastinum. Starting with either the RaB or Linear EBUS both have their pros and cons. The benefit to performance of a linear EBUS first is the potential to obviate the need for peripheral nodule biopsy by obtaining rapid, on-site pathologic feedback of occult nodal disease, reducing some of the risk of the procedure (i.e. bleeding and pneumothorax).6 Conversely, the pitfalls to performing linear EBUS first is the possible contribution of atelectasis resultant of the increased time from intubation to peripheral nodule biopsy, blood in the airway causing bronchospasm, and resorption atelectasis from hyperoxia9. There are no prospective data evaluating this in a randomized fashion, but one Monte Carlo simulation (with assumption of diagnostic yield from navigational bronchoscopy of 70% when performed first and 60% when performed second) suggested a higher diagnostic yield and less need for repeat procedure in the navigation first group, despite a 10% assumption of occult nodal disease10.\n\nAs outlined in the specific aims above, the overarching goals of this study are to assess in a multicenter, randomized clinical trial performed by members of the Interventional Pulmonary Outcomes Group (IPOG), whether sequence of staging EBUS plays a role in diagnostic yield, incidence of atelectasis, and safety outcomes in patients undergoing RaB.",[29],"2024-11-05",{"date":448,"type":43},"2024-11-06",{"date":424,"type":21},{"date":451,"type":21},"2027-04-01",{"name":453,"class":50},"Northwestern University"]